Press coverage about Achaogen (NASDAQ:AKAO) has trended somewhat positive on Monday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Achaogen earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 36 out of 100, indicating that recent news coverage is unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

Several brokerages recently issued reports on AKAO. Zacks Investment Research lowered Achaogen from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Wedbush reiterated an “outperform” rating and issued a $28.00 price objective on shares of Achaogen in a research report on Monday, April 24th. HC Wainwright began coverage on Achaogen in a research report on Thursday, June 15th. They issued a “buy” rating and a $29.00 price objective for the company. ValuEngine upgraded Achaogen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Cowen and Company reiterated an “outperform” rating on shares of Achaogen in a research report on Friday, May 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $25.58.

Achaogen (AKAO) opened at 24.19 on Monday. The company has a 50 day moving average price of $22.71 and a 200 day moving average price of $20.86. Achaogen has a 12 month low of $3.36 and a 12 month high of $27.79. The firm’s market capitalization is $867.28 million.

Achaogen (NASDAQ:AKAO) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.39. Achaogen had a negative return on equity of 119.78% and a negative net margin of 212.71%. The business had revenue of $7.46 million for the quarter, compared to analyst estimates of $3.81 million. During the same period in the prior year, the business earned ($0.66) EPS. The company’s revenue for the quarter was up 27.7% on a year-over-year basis. Analysts anticipate that Achaogen will post ($2.63) earnings per share for the current fiscal year.

In related news, CFO Tobin Schilke sold 2,066 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $21.53, for a total transaction of $44,480.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 13.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at

About Achaogen

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Insider Buying and Selling by Quarter for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.